Live Breaking News & Updates on Indaptus Therapeutics Inc
Stay updated with breaking news from Indaptus therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) was down 10.1% during trading on Thursday . The stock traded as low as $2.40 and last traded at $2.48. Approximately 40,955 shares changed hands during mid-day trading, a decline of 30% from the average daily volume of 58,922 shares. The stock had previously closed at $2.76. […] ....
Indaptus Therapeutics, Inc. announced the successful advancement of its Phase 1 trial for Decoy20, an investigational novel package of broad immune agonists for cancer immunotherapy that has. ....
HC Wainwright restated their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP – Free Report) in a research note released on Monday morning, Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) […] ....
HC Wainwright reaffirmed their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP – Free Report) in a research note issued to investors on Monday, Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) […] ....